GlassScriptPhysician profile
Felix A Morris
NPI 1689613739
$14,997.97
in general payments reported to CMS, 2019-2025
40 companies · $2,741 in 2025
The $2,741 reported for 2025 was more than what 91% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,735 · 2020: $1,657 · 2021: $1,688 · 2022: $2,243 · 2023: $2,090 · 2024: $2,845 · 2025: $2,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,546 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,545.52 |
| Education | $129.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,313.55 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,359.96 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,339.10 | 2019-2025 | Ofev, Jascayd |
| Jazz Pharmaceuticals INC. | $1,214.07 | 2019-2025 | |
| Harmony Biosciences LLC | $893.44 | 2020-2025 | Wakix |
| Insmed, INC. | $781.60 | 2019-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $601.91 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $549.42 | 2019-2024 | Yupelri |
| Abbvie INC. | $513.70 | 2021-2025 | |
| Genzyme Corporation | $424.61 | 2022-2025 | |
| Grifols USA, LLC | $368.80 | 2019-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $334.79 | 2021-2025 | Glassia |
| Axsome Therapeutics, INC. | $237.16 | 2022-2025 | Sunosi |
| Merck Sharp & Dohme LLC | $235.36 | 2021-2025 | Zerbaxa, Dificid, Recarbrio |
| Actelion Pharmaceuticals US, INC. | $160.46 | 2019-2024 | Uptravi |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $149.88 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Astellas Pharma US INC | $149.06 | 2019-2022 | |
| Gilead Sciences, INC. | $130.74 | 2019-2021 | |
| United Therapeutics Corporation | $121.15 | 2019-2025 | Tyvaso, Tyvaso |
| Avadel Cns Pharmaceuticals, LLC | $120.11 | 2024-2025 | Lumryz |
| Lilly USA, LLC | $110.16 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $104.50 | 2022-2024 | Tezspire |
| Vifor Pharma, INC. | $90.16 | 2024 | Zemaira |
| Idorsia Pharmaceuticals US INC | $80.73 | 2023-2024 | Quviviq |
| Inspire Medical Systems, INC. | $80.53 | 2023-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Allergan, INC. | $74.07 | 2019-2020 | |
| Verona Pharma, INC. | $57.86 | 2025 | Ohtuvayre |
| Eisai INC. | $52.66 | 2020-2021 | |
| Electromed, INC. | $43.71 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $34.87 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.48 | 2019-2021 | |
| Viatris Specialty LLC | $29.30 | 2025 | Yupelri |
| Resmed Corp | $22.25 | 2023 | |
| Baxter Healthcare | $21.44 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Medtronic, INC. | $19.93 | 2024 | Illumisite |
| Pulmonx Corporation | $19.86 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.51 | 2021 | |
| 3b Medical, INC. | $17.04 | 2025 | Luna |
| Shire North American Group INC | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felix Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.